The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | TGR-1202- a new generation PI3K delta inhibitor for CLL
Javier Pinilla-Ibarz, MD, PhD from the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL discusses a new generation PI3K delta inhibitor used in chronic lymphocytic leukemia (CLL) called TGR-1202. Surprisingly TGR-1202 has a significantly better tolerability profile compared to other PI3K delta inhibitors. This interview was recorded at the International Workshop on Chronic lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
